Health insurance company Clover Health (NASDAQ:CLOV) will be reporting results tomorrow afternoon. Here’s what to look for.
Clover Health missed analysts’ revenue expectations by 4.5% last quarter, reporting revenues of $331 million, up 8.2% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations. It added 849 customers to reach a total of 81,110.
Is Clover Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Clover Health’s revenue to decline 31.7% year on year to $348.7 million, improving from the 43.2% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.07 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Clover Health has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Clover Health’s peers in the health insurance providers segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Cencora delivered year-on-year revenue growth of 12.8%, beating analysts’ expectations by 5.2%, and Centene reported revenues up 3.4%, topping estimates by 4.4%. Cencora traded down 2.2% following the results while Centene was also down 6.3%.
Read our full analysis of Cencora’s results here and Centene’s results here.
Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The U.S. Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the health insurance providers stocks have shown solid performance, the group has generally underperformed, with share prices down 4.4% on average over the last month. Clover Health is down 5.9% during the same time and is heading into earnings with an average analyst price target of $4.80 (compared to the current share price of $4.33).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
